descriptionPublicationkeyboard_double_arrow_right Article 27 Jul 2011Publisher:WileyJournal:Clinical Pharmacology & Therapeutics, volume 90, pages 461-466 (issn: 0009-9236, eissn: 1532-6535,

Authors: S. W. Paugh; STOCCO, GABRIELE; J. R. McCorkle; B. Diouf; K. R. Crews; W. E. Evans;

doi: 10.1038/clpt.2011.126

pmid: 21796115

pmc: PMC3646359

handle: 11368/2692209

Cancer Pharmacogenomics

- Summary
- Subjects
- Metrics

Abstract

Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of pharmacogenomics to the clinic. This review addresses how inherited (germline) and acquired (somatic) sources of genome variability can alter the toxicity or efficacy of cancer chemotherapy.

Related Organizations

University of Trieste
Italy
St. Jude Children's Research Hospital
United States

Keywords

pharmacogenomic, Treatment Outcome, Genome, Human, Pharmacogenetics, childhood acute lymphoblastic leukemia, Neoplasms, Humans, pharmacogenomics; childhood acute lymphoblastic leukemia, Precision Medicine

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	35
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%